Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using felodipine and hesperetin in combination in wistar rats and everted rat gut sacs in vitro

Phytotherapy Research

Volumn 28, Issue 5, 2014, Pages 699-705

  Sridhar, V ^a   Surya Sandeep, M ^a   Ravindra Babu, P ^a   Naveen Babu, K ^a  

^a KVSR SIDDHARTHA COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

CYP3A4; dihydropyridines; felodipine; flavanones; hesperetin; P glycoprotein

Indexed keywords

CYTOCHROME P450 3A; FELODIPINE; HESPERETIN; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TRANSPORT; ENZYME INHIBITION; FIRST PASS EFFECT; IN VITRO STUDY; INTESTINE; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MEMBRANE PERMEABILITY; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; RAT;

RATTUS; RATTUS NORVEGICUS;

CYP3A4; DIHYDROPYRIDINES; FELODIPINE; FLAVANONES; HESPERETIN; P-GLYCOPROTEIN;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 CYP3A; FELODIPINE; HALF-LIFE; HESPERIDIN; ILEUM; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEINS; RATS; RATS, WISTAR; VERAPAMIL;

EID: 84899494127     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5040     Document Type: Article

References (43)

1. Aranganathan S, Panneer Selvam J, Nalini N,. 2008. Hesperetin exerts dose dependent chemopreventive effect against 1, 2-dimethyl hydrazine induced rat colon carcinogenesis. Invest New Drugs 27: 203-213.
2. Bailey DG, Spence JD, Munoz C, Arnold JM,. 1991. Interaction of citrus juices with felodipine and nifedipine. Lancet 337: 268-269.
3. Bansal T, Jaggi M, Khar RK, Talegaonkar S,. 2009. Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy. J Pharm Pharmaceut Sci 12: 46-78.
4. Barthe L, Woodley J, Houin G,. 1999. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 13: 154-168.
5. Benet LZ, Wu C-Y,. 2003. Disposition of tacrolimus in isolated perfused rat liver: Influence of troleandomycin, cyclosporine, and GG918. Drug Metab Dispos 31: 1292-1295.
6. Capraro J, Clemente A, Rubio LA, Magni C, Scarafoni A, Duranti M,. 2011. Assessment of the lupin seed glucose-lowering protein intestinal absorption by using in vitro and ex vivo models. Food Chem 125: 1279-1283.
7. Collett A, Tanianis-Hughes J,. 2005. Comparison of P-glycoprotein- mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci 26: 386-93.
8. Cook NC, Samman S,. 1996. Flavonoids-chemistry, metabolism, cardio protective effects and dietary sources. J Nutr Biochem 7: 66-76.
9. Di Majo D, Giammanco M, La Guardia M, Tripoli E, Giammanco S, Finotti E,. 2005. Flavanones in Citrus fruit: Structure antioxidant activity relationships. Food Res Int 38: 1161-1166.
10. Fang S-H, Hou Y-C, Chao P-DL,. 2005. Pharmacokinetic and pharmacodynamic interactions of morin and cyclosporine. Toxicol Appl Pharmacol 205: 65-70.
11. Fenner KS, Troutman MD, Kempshall S, et al,. 2009. Drug-Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro- InVivo Correlation Using Digoxin as a Probe Drug. Clin Pharmacol Ther 85: 173-181.
12. Ferrari R, Cargnoni A, Bernocchi P, et al,. 1996. Effects of felodipine on the ischemic heart: Insight into the mechanism of cytoprotection. Cardiovasc Drugs Ther 10: 425-437.
13. Hansten PD, Horn JR,. 2008. Cytochrome P450 Enzymes and Drug Interactions, Table of Cytochrome P450 Substrates, Inhibitors, Inducers and P-glycoprotein, with Footnotes. In The Top 100 Drug Interactions-A guide to Patient Management, 2008 Edition. Freeland, WA: H&H Publications, 142-157.
14. Henderson L, Yue QY, Bergquist C,. 2002. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54: 349-356.
15. Hertog MG, Hollman PCH, Katan MB, Kromhout D,. 1993. Dietary antioxidant flavonoids and risk of coronary heart disease. Lancet 342: 1007-1011.
16. Hishikawa K, Lüscher TF,. 1998. Felodipine Inhibits Free-Radical Production by Cytokines and Glucose in Human Smooth Muscle Cells. Hypertension 32: 1011-1015.
17. Hollman PC, Katan MB,. 1999. Health effects and bioavailability of dietary flavonols. Free Radicals Res 31: S75-S80 (Suppl).
18. Huang Y-C, Liu K-C, Chiou Y-L,. 2012. Melanogenesis of murine melanoma cells induced by hesperetin, a Citrus hydrolysate-derived falconoid. Food Chem Toxicol 50: 653-659.
19. Jeon SM, Kim HK, Kim HJ, Do GM, Jeong TS, Park YB,. 2007. Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats. Transl Res 149: 15-21.
20. Jiunn H, Lin JH,. 2003. D rug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55: 53-81.
21. Joshipura KJ, Ascherio A, Manson JE, Stampfer MJ, Rimm EB, Speizer FE,. 1999. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 282: 1233-1239.
22. Kallem RR, Ramesh M, Seshagirirao JVLN,. 2013. Validated LC-ESI-MS/MS method for simultaneous quantitation of felodipine and metoprolol in rat plasma: application to a pharmacokinetic study in rats. Biomed Chromatogr DOI: 10.1002/bmc.2861
23. Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I,. 2007. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr 61: 472-477.
24. Kazda S, Knorr A,. 1990. Handbook of Experimental Pharmacology, Pharmacology of Antihypertensive Therapeutics, vol. 93. Berlin: Springer-Verlag, 301.
25. Kharasch ED, Walker A, Hoffer C, Sheffels P,. 2005. Evaluation of First-Pass Cytochrome P4503A (CYP3A) and P-Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination. J Clin Pharmacol 45: 79-88.
26. Kim HK, Jeong T-S, Lee M-K, Park YB, Choi M-S,. 2003. Lipid-lowering efficacy of hesperetin metabolites in high-cholesterol fed rats. Clin Chim Acta 327: 129-137.
27. Landolfi R, Mower RL, Steiner M,. 1984. Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations. Biochem Pharmacol 33: 1525-1530.
28. 3 Adenosine Receptor Antagonists. J Med Chem 41: 3186-3201.
29. Li M, Si L, Pan H, et al,. 2011. Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: Assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. Int J Pharm 403: 37-45.
30. Liu L, Xu DM, Cheng YY,. 2008. Distinct effects of naringenin and hesperetin on nitric oxide production from endothelial cells. J Agric Food Chem 56: 824-829.
31. Madsen JK, Jensen JD, Jensen LW,. 1996. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol 50: 203-208.
32. Neerati P, Gade J,. 2011. Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. Eur J Pharm Sci 42: 285-289.
33. Ravindra P, Naveen Babu K, Haroled Peter PL, Rajesh K, Jawahar Babu P,. 2013. Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. Drug Dev Ind Pharm 39: 873-879.
34. Schuetz EG, Beck WT, Schuetz JD,. 1996. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately upregulate these proteins in human colon carcinoma cells. Mol Pharmacol 49: 311-318.
35. Spencer JP,. 2009. Flavonoids and brain health: multiple effects underpinned by common mechanisms. Genes Nutr 4: 243-250.
36. Tzeng SH, Ko WC, Ko FN, Teng CM,. 1991. Inhibition of platelet aggregation by some flavonoids. Thromb Res 64: 91-100.
37. Venkatesh RC, Babu PR, Challa SR, Johnson B, Maheswari C,. 2013. Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Drug Dev Ind Pharm 39: 865-872.
38. Vlase L,. 2010. Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers. A prospective pilot study. Curr Ther Res 71: 360-368.
39. Wacher VJ, Wu CY, Benet LZ,. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134.
40. Wang YH, Chao PD, Hsiu SL, Wen KC, Hou YC,. 2004. Lethal quercetin-digoxin interaction in pigs. Life Sci 74: 1191-1197.
41. Yamreudeewong W, DeBisschop M, Martin LG,. 2003. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 26: 421-438.
42. Ye L, Chan FL, Chen S, Leung LK,. 2012. The citrus falconine hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice. J Nutr Biochem 23: 1230-1237.
43. Zrieki A, Farinotti R, Buyse M,. 2010. Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. Eur J Pharmacol 636: 189-197.